Precision medicine for mood disorders: objective assessment, risk prediction, pharmacogenomics, and repurposed drugs
Le-Niculescu H, Roseberry K, Gill SS, Levey DF, Phalen PL, Mullen J, Williams A, Bhairo S, Voegtline T, Davis H, Shekhar A, Kurian SM, Niculescu AB. Precision medicine for mood disorders: objective assessment, risk prediction, pharmacogenomics, and repurposed drugs. Molecular Psychiatry 2021, 26: 2776-2804. PMID: 33828235, PMCID: PMC8505261, DOI: 10.1038/s41380-021-01061-w.Peer-Reviewed Original ResearchMeSH KeywordsDrug RepositioningHumansMood DisordersPharmacogeneticsPrecision MedicineReproducibility of ResultsRisk AssessmentConceptsBlood gene expression biomarkersTop candidate biomarkersMood disordersIndependent cohortStrongest overall evidenceBlood testsTop biomarkersGene expression biomarkersCandidate biomarkersConvergent functional genomics approachMood statesPotential new antidepressantsPsychiatric disorder patientsOverall evidenceVisual analog scaleSimple visual analog scaleMatching of patientsPanel of biomarkersPrecision medicineMonitoring of responseBipolar mood disorderExpression biomarkersCell differentiation functionsObjective assessmentSevere mania